Vladonix: clinical report on a tissue-derived preparation
Comparison in people · 2006
- What was studied
- 76 patients: 42 adjunctive Vladonix; 34 controls. Prior low-dose radiation exposure or radiation/chemotherapy.
- Main finding
- In the 76-person institute report, CD4-positive cells were 34.6% after adjunctive oral Vladonix and 30.8% after usual care, compared with a shared 28.5% baseline column.
Reported findings and study design
42 received adjunctive Vladonix and 34 conventional treatment alone. Peripheral-blood immunophenotyping used immunofluorescence. Immunoglobulins were measured by radial immunodiffusion.
Population or model 76 patients: 42 adjunctive Vladonix; 34 controls. Prior low-dose radiation exposure or radiation/chemotherapy.
Dose, route and schedule
One to three oral capsules, two to three times daily before meals for 15–20 days. The report lists 10 mg of thymus extract per capsule. Both arms received conventional care.
Protocol source ↗ · Russian institute-report reproductions, methods and Table 2
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| CD4-positive cells | 34.6% vs 30.8% | Vladonix plus usual care versus usual care. Shared baseline 28.5%. · Vladonix value marked p < 0.05 versus baseline. |
| CD3-positive cells | 55.7% vs 51.9% | Shared baseline 46.5%. · Vladonix value marked p < 0.05 versus baseline. |
| CD4/CD8 ratio | 1.4 vs 1.2 | Shared baseline 1.1. · Vladonix value marked p < 0.05 versus baseline. |
| IgM, IgG, IgA and CD8-positive cells | No significant change marked | Table 2 significance markers do not apply to these rows. |
The report provides a shared baseline column and no clear between-arm test. Its biomarker results do not establish fewer infections or better cancer outcomes.
Source for these results ↗ · Reviewed 2026-11-13
Study limitations and source details
Study limitations
- Sex counts differ between prose and table. Immune biomarkers do not establish protection from radiation, fewer infections or improved cancer outcomes.
- Commercially reproduced institute report; independent peer review and independent replication are not established by this document.
- Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.
Source details
Institute report — commercial reproduction
Russian institute-report reproductions, methods and Table 2
Sources checked
Citation
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution). Vladonix: clinical report on a tissue-derived preparation Institute clinical report (commercial reproduction); 2006 study/report date, not website publication date